ClinicalTrials.gg
CompletedNCT00492726Updated Nov 7, 2014Results posted

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

A Phase 3 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Ertapenem intravenous in Infection, sponsored by Bayer. Completed at 52 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-07.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
804
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.

02

Conditions studied

  • Infection

Browse trials for

Keywords

  • Complicated Intra-Abdominal Infections
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 804 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized men or women >/=18 years of age
  • Expected duration of treatment with intravenous antibiotics anticipated to be >/= 5 full days but not exceeding 14 days
  • Ability to provide documented and signed written
  • Confirmed or suspected intra abdominal infection defined as follows:

    • For a confirmed intra abdominal infection, a surgical procedure (laparotomy or laparoscopy) must have been performed within 24 hours prior to enrollment and reveal at least one of the following:

      • Gross peritoneal inflammation with purulent exudates (i.e. peritonitis)
      • Intra abdominal abscess
      • Macroscopic intestinal perforation with localized or diffuse peritonitis
  • Subjects enrolled on the basis of a suspected intra abdominal infection must have:

    • Radiological evidence [abdominal plain films, computed tomography (CT), magnetic resonance imaging (MRI) or ultrasound] of gastrointestinal perforation or intra-abdominal abscess and the following signs and symptoms:

      • Symptoms referable to the abdominal cavity (e.g. anorexia, nausea, vomiting or pain), lasting for at least 24 hours
      • Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity
    • At least two of the following SIRS criteria:

      • Temperature > 38.0°C rectal or tympanic membrane, or temperature \< 36.0°C rectal or tympanic
      • Heart rate > 90/min
      • Respiratory rate > 20/min
      • WBC >12,000 cells/mm3 or \< 4,000 cells/ mm3
    • The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) within 24 hours of enrollment of the study

Exclusion criteria

Exclusion Criteria:

  • Known to quinolones, and/or to carbapenems and/or to any other type of beta lactam antibiotic drugs (e.g. penicillins or cephalosporins), or any of the
  • Women who are pregnant or lactating or in whom pregnancy cannot be excluded
  • History of tendon disease/disorder related to quinolone treatment
  • Known congenital or documented acquired ; uncorrected hypokalemia; bradycardia; clinically relevant heart failure with reduced ; previous history of symptomatic arrhythmias
  • Concomitant use of any of the following drugs, reported to increase the QT interval: antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide) or antiarrhythmics class III (e.g., amiodarone, sotalol, dofetilide, ibutilide), neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride), tricyclic antidepressive agents, certain antimicrobials (sparfloxacin, erythromycin IV, pentamidine, antimalarials, particularly halofantrine), certain antihistaminics (terfenadine, astemizole, mizolastine), and others (cisapride, vincamine IV, bepridil, diphemanil)
  • Known severe end stage liver disease
  • \</= 30 mL/min/1.73 m2
  • Systemic antibacterial therapy administered for more than 24 hours within 7 days of enrollment
  • Need for systemic antibacterial therapy with agents other than those described in the study protocol
  • Indwelling peritoneal catheter
  • Pre existing ascites and presumed spontaneous bacterial peritonitis
  • Perforation of the stomach or duodenum, if the duration of perforation is less than 24 hours or if operated on within 24 hours of perforation
  • Perforation of the small bowel (excluding the duodenum) or large bowel, if the duration of perforation is less than 12 hours or if operated on within 12 hours of perforation
  • All pancreatic processes including pancreatic sepsis, peri-pancreatic sepsis, or an intra abdominal infection secondary to pancreatitis
  • Liver and splenic abscess
  • Transmural bowel ischemia or necrosis without perforation or established peritonitis or abscess
  • Acute and gangrenous cholecystitis without perforation
  • Acute cholangitis
  • Early acute, suppurative, or gangrenous non-perforated appendicitis
  • Subjects requiring antibiotic irrigations of the abdominal cavity or surgical wound
  • Treatment with "open abdomen" or marsupialization, or multiple planned re laparotomies
  • Infections originating from the female genital tract
  • Peri-nephric infections
  • Evidence of sepsis with shock requiring the administration of vasopressors for more than 4 consecutive hours
  • Known rapidly fatal underlying disease (death expected within 6 months)
  • Neutropenia ( \< 1,000/mL) caused by therapy or
  • Receiving chronic treatment with known immunosuppressant therapy (including chronic treatment with > 15 mg/day of systemic prednisone or equivalent)
  • Subjects known to have AIDS ( \< 200/mL) or seropositives who are receiving HAART (HIV positive subjects may be included. HIV testing is not required for this study protocol)
  • Subjects with a malignant or pre malignant hematological condition, including Hodgkin's disease and non-Hodgkin lymphoma (subjects with solid tumor can be included in the study)
  • Subjects with a >/= 45 kg/m2
  • Previous enrollment in this study
  • Participation in any clinical drug study within the previous 4 weeks
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
804 participants (actual)

Study arms

  • Experimental
    Moxifloxacin (Avelox, BAY12-8039)

    Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.

    Drug: Moxifloxacin (Avelox, BAY12-8039)

  • Active comparator
    Ertapenem

    Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.

    Drug: Ertapenem intravenous

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population

    Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.

    Time frame: 21 to 28 days after completion of study drug therapy

Secondary outcomes

  1. Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population

    Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.

    Time frame: During treatment at day 5 +/- 1 day

  2. Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)

    Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.

    Time frame: During treatment at day 5 +/- 1 day

  3. Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population

    Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.

    Time frame: after 5 - 14 days of therapy

  4. Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)

    Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.

    Time frame: After 5 - 14 days of therapy

  5. Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)

    Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.

    Time frame: 21 - 28 days after end of therapy

  6. Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)

    Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.

    Time frame: 21 - 28 days after end of therapy

  7. Number of Subjects Who Died Due to Intra-abdominal Infections

    Number of subjects who had died due to intra abdominal infections by the time of TOC visit.

    Time frame: 21 - 28 days after end of treatment at TOC Visit

  8. Duration of Hospitalization

    Duration of hospitalization in the per protocol population.

    Time frame: From the first admission date to the discharge date (from 4 to 71 days after start of study medication)

  9. Duration of Hospitalization Postoperatively

    Duration of hospitalization after the first surgery until discharge in the per protocol population.

    Time frame: Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication)

07

Results

Posted Mar 3, 2010

Participant flow

Subjects were enrolled from 02 July 2006 to 31 December 2008 at 52 centers in 14 countries: Argentina (9), Belgium (3), Bulgaria (4), Estonia (3), France (2 ), Germany (5), Greece (1), Israel (2), Latvia (6), Lithuania (4), Romania (5), Russia (3), South Africa (3), and Spain (2).

Participant flow — Overall Study
MilestoneMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Started410394
End of treatment (eot, day 5 to 14)387377
End of study360358
Completed360358
Not completed5036
Withdrew: Adverse event106
Withdrew: Death72
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up2719
Withdrew: Physician decision01
Withdrew: Withdrawal by subject63
Withdrew: Non compliant with study medication03

Outcome measures

PrimaryNumber of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population

Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.

Time frame:
21 to 28 days after completion of study drug therapy
Reported as:
Number · participants
Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Clinical Cure315324
Clinical Failure3723
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference of cure rates (in percent): -3.8 · 95% CI -7.9 to 0.4A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.
SecondaryNumber of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population

Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.

Time frame:
During treatment at day 5 +/- 1 day
Reported as:
Number · participants
Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Clinical Improvement210194
Clinical Failure02
Missing142151
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference in improvement rates (in %): 1.1 · 95% CI -0.4 to 2.7A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.
SecondaryNumber of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)

Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.

Time frame:
During treatment at day 5 +/- 1 day
Reported as:
Number · participants
Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Eradication55
Presumed Eradication170149
Persistence167
Presumed Persistence02
Superinfections01
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference in bact. success rates (in %): -3.9 · 95% CI -8.8 to 1.0A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group. Presumed eradications and eradications without superinfection were considered bacteriological successes.
SecondaryNumber of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population

Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.

Time frame:
after 5 - 14 days of therapy
Reported as:
Number · participants
Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Clinical Cure328330
Clinical Failure2317
Missing10
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference of cure rates (in percent): -1.5 · 95% CI -5.0 to 1.9A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.
SecondaryNumber of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)

Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.

Time frame:
After 5 - 14 days of therapy
Reported as:
Number · participants
Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Eradication57
Presumed Eradication257247
Persistence209
Presumed Persistence1311
Superinfections12
Indeterminate/missing10
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference in bact. success rates (in %): -3.9 · 95% CI -8.8 to 1.0A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group. Presumed eradications and eradications without superinfection were considered bacteriological successes.
SecondaryNumber of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)

Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.

Time frame:
21 - 28 days after end of therapy
Reported as:
Number · participants
Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Eradication00
Presumed Eradication257249
Persistence209
Presumed Persistence2018
Superinfections00
Reinfections00
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference in bact. success rates (in %): -3.8 · 95% CI -9.0 to 1.5A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group. Presumed eradications and eradications without super- or reinfection were considered bacteriological successes.
SecondaryNumber of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)

Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.

Time frame:
21 - 28 days after end of therapy
Reported as:
Number · participants
Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Clinical Cure265254
Clinical Failure3222
Statistical analysis
  • Moxifloxacin (Avelox, BAY12-8039) vs Ertapenem · Difference of cure rates (in percent): -2.9 · 95% CI -7.6 to 1.9A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.
SecondaryNumber of Subjects Who Died Due to Intra-abdominal Infections

Number of subjects who had died due to intra abdominal infections by the time of TOC visit.

Time frame:
21 - 28 days after end of treatment at TOC Visit
Reported as:
Number · participants
Number of Subjects Who Died Due to Intra-abdominal Infections
participantsMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Yes31
No349346
SecondaryDuration of Hospitalization

Duration of hospitalization in the per protocol population.

Time frame:
From the first admission date to the discharge date (from 4 to 71 days after start of study medication)
Reported as:
Mean · days
Duration of Hospitalization
daysMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Duration of Hospitalization11.7 ± 7.311.2 ± 7.8
SecondaryDuration of Hospitalization Postoperatively

Duration of hospitalization after the first surgery until discharge in the per protocol population.

Time frame:
Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication)
Reported as:
Mean · days
Duration of Hospitalization Postoperatively
daysMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Duration of Hospitalization Postoperatively11.1 ± 7.110.7 ± 7.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moxifloxacin (Avelox, BAY12-8039)—60/408 (14.7%)115/408 (28.2%)
Ertapenem—48/390 (12.3%)87/390 (22.3%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Wound infectionInfections and infestations10/4081/390
Cardiac arrestCardiac disorders7/4082/390
PneumoniaInfections and infestations1/4084/390
Multi-organ failureGeneral disorders4/4082/390
Unevaluable eventGeneral disorders4/4082/390
Renal failure acuteRenal and urinary disorders4/4081/390
Intestinal fistulaGastrointestinal disorders1/4083/390
PeritonitisGastrointestinal disorders3/4082/390
SepsisInfections and infestations3/4081/390
Septic shockInfections and infestations3/4080/390
Most frequent other events
Most frequent other events
EventMoxifloxacin (Avelox, BAY12-8039)Ertapenem
Wound infectionInfections and infestations37/40828/390
NauseaGastrointestinal disorders30/40817/390
Lipase increasedInvestigations25/40824/390
DiarrhoeaGastrointestinal disorders23/40818/390

Baseline characteristics

Age, Continuous
Age, Continuous(years)Moxifloxacin (Avelox, BAY12-8039)ErtapenemTotal
Mean48.1 ± 18.347.0 ± 18.247.4 ± 18.2
Sex: Female, Male
Sex: Female, Male(Participants)Moxifloxacin (Avelox, BAY12-8039)ErtapenemTotal
Female156131287
Male254263517
08

Study locations

52 sites
  • Ciudadela, Buenos Aires B1702FWM, Argentina
  • de Febrero 3, Buenos Aires 1657, Argentina
  • Florencio Varela, Buenos Aires 1888, Argentina
  • Merlo, Buenos Aires B1712FJN, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1180AAX, Argentina
  • Rosario, Santa Fe, Argentina
  • Capital Federal, Argentina
  • Córdoba, 5000, Argentina
  • Mendoza, Argentina
  • Bruxelles - Brussel, 1070, Belgium
  • Bruxelles - Brussel, 1090, Belgium
  • Gent, 9000, Belgium
  • Pleven, 5800, Bulgaria
  • Rousse, 7002, Bulgaria
  • Sofia, 1431, Bulgaria
  • Sofia, 1606, Bulgaria
  • Kohtla-Jarve, 30322, Estonia
  • Tallin, EE-13419, Estonia
  • Tartu, EE-51014, Estonia
  • Amilly Cedex, 45207, France
  • Besancon, 25000, France
  • Heidelberg, Baden-Württemberg 69120, Germany
  • Beeskow, Brandenburg 15848, Germany
  • Hannover, Niedersachsen 30625, Germany
  • Paderborn, Nordrhein-Westfalen 33098, Germany
  • Homburg, Saarland 66424, Germany
  • Rio Patras, 265 00, Greece
  • Haifa, 31048, Israel
  • Kfar Saba, 4428164, Israel
  • Daugavpils, LV-5417, Latvia
  • Liepaja, 3402, Latvia
  • Rezekne, Latvia
  • Riga, 1002, Latvia
  • Riga, LV-1038, Latvia
  • Valmiera, LV-4201, Latvia
  • Kaunas, 45130, Lithuania
  • Klaipeda, LT-92231, Lithuania
  • Vilnius, 10207, Lithuania
  • Vilnius, LT-04130, Lithuania
  • Brasov, Romania
  • Bucharest, 022328, Romania
  • Cluj-Napoca, 400006, Romania
  • Oradea, Romania
  • Timisoara, 300748, Romania
  • Moscow, 115280, Russian Federation
  • Moscow, 119048, Russian Federation
  • Smolensk, 214019, Russian Federation
  • Cape Town, Cape 7500, South Africa
  • Pretoria, Gauteng 0001, South Africa
  • Somerset West, Western Cape 7130, South Africa
  • L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Madrid, 28007, Spain
09

References and documents

Publications

  • De Waele JJ, Tellado JM, Alder J, Reimnitz P, Jensen M, Hampel B, Arvis P. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Int J Antimicrob Agents. 2013 Jan;41(1):57-64. doi: 10.1016/j.ijantimicag.2012.08.013. Epub 2012 Nov 13. PubMed 23153963 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2007
First posted
Jun 27, 2007
Start
Jul 2006
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Mar 3, 2010
Last update
Nov 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00492726
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 27, 2007
Start date
Jul 2006
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Mar 3, 2010
Last update
Nov 7, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moxifloxacin

Start the discussion